反応式
CS(N(C(=O)[C@H](CC1C=CC=CC=1)N)N)(=O)=[O:3].[Cl:18][C:19]1[CH:36]=[CH:35][C:22]2[O:23][C:24]3[CH:34]=[CH:33][CH:32]=[CH:31][C:25]=3[CH2:26][N:27]([C:28](Cl)=[O:29])[C:21]=2[CH:20]=1>>[Cl:18][C:19]1[CH:36]=[CH:35][C:22]2[O:23][C:24]3[CH:34]=[CH:33][CH:32]=[CH:31][C:25]=3[CH2:26][N:27]([C:28]([OH:3])=[O:29])[C:21]=2[CH:20]=1参加物
3
実験手順
8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2,[2-[(methylsulfonyl)amino]-1-oxo-3-phenyl]hydrazide (15) was prepared in the manner described above in Example 5 on a 0.51 mmol scale starting with N-(methylsulfonyl)-L-phenylalanine, hydrazide (14), prepared as described above in Example 14, and 8-chlorodibenz[b,f][1,4]-oxazepine-10(11H)-carbonyl chloride (2), prepared as described above in Example 2, to yield 0.11 g (42%) of product.
後処理
- customprepared
- customprepared
出典と根拠
- ORDレコード
- ord-3b32e8c689a04fcb9c08536b5c1c1120
- 出典データセット
- uspto-grants-1995_02
- 特許番号
- US05393747
関連ノート
読み込み中…